Recombinant Activated Factor VII for Postoperative Hemorrhage Following Repair of Acute Type A Aortic Dissection
DOI:
https://doi.org/10.1532/HSF98.20101027Abstract
Background: Perioperative hemorrhage in the repair of acute type A aortic dissection increases morbidity, mortality, and costs of treatment. Recombinant activated factor VII (rFVIIa) mitigates intractable blood loss in surgery. By enhancing thrombin generation on activated platelet surfaces and activating thrombin-activatable fibrinolysis inhibitor and factor XIII, rFVIIa promotes platelet aggregation and fibrin plug formation at the site of endothelial injury. We report outcomes for type A aortic dissection patients treated postoperatively with rFVIIa for life-threatening hemorrhage.
Methods: Patients charts were reviewed to gather demographic, procedural, and laboratory data as well as information regarding clinical outcomes and blood product use.
Results: Nine patients with acute type A aortic dissection received rFVIIa in the perioperative period. In the 6 hour period after rFVIIa treatment, transfusion of blood products was reduced. The international normalized ratio decreased after treatment (1.6 versus 0.9, P < .01). One patient experienced perioperative stroke.
Conclusions: In patients with acute type A aortic dissections who have life-threatening bleeding, early administration of rFVIIa may safely normalize coagulation variables, decrease transfusion requirements, and enhance hemostasis.
References
Abshire T, Kenet G. 2004. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2:899-909.nAiken MG. 2004. Recombinant factor VIIa. Emerg Med Australas 16:446-55.nBishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. 2006. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 81:875-9.nDiprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. 2005. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95:596-602.nDutton RP, McCunn M, Hyder M, et al. 2004. Factor VIIa for correction of traumatic coagulopathy. J Trauma 57:709-18.nFilsoufi F, Castillo JG, Rahmanian PB, et al. 2006. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. Ann Thorac Surg 82:1779-83.nFriederich PW, Henny CP, Messelink EJ, et al. 2003. Effect of recombinant activated factor VII on perioperative blood loss in patients under-going retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201-5.nGill R, Herbertson M, Vuylsteke A, et al. 2009. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 120:21-7.nHagan PG, Nienaber CA, Isselbacher EM, et al. 2000. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 283:897-903.nHedner U. 2006. Mechanism of action of recombinant activated factor VII: an update Semin Hematol. 43:S105-7.nHyllner M, Houltz E, Jeppsson A. 2005. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 28:254-8.nKarkouti K, Beattie WS, Wijeysundera DN, et al. 2005. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45:26-34.nLoudon B, Smith MP. 2005. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J 35:463-7.nLusher JM. 1998. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 63:7-10.nMaugeri N, Brambilla M, Camera M, et al. 2006. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 4:1323-30.nMayer SA, Brun NC, Begtrup K, et al. 2005. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352:777-85.nMoore FA, Moore EE, Sauaia A. 1997. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 132:620-4.nRaivio P, Suojaranta-Ylinen R, Kuitunen AH. 2005. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 80:66-71.nRomagnoli S, Bevilacqua S, Gelsomino S, et al. 2006. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 102:1320-6.nShander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. 2010. Activity-based costs of blood transfusion in surgical patients at four hospitals. Transfusion 50:753-65.nShapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. 1998. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80:773-8.nWarren O, Mandal K, Hadjianastassiou V, et al. 2007. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 83:707-14.n
